Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Conference News THT 2024

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

Michael O'Riordan

March 08, 2024

Presentation THT 2024

Regulatory Issues Related to the Introduction of New Percutaneous Pumps

Presenter: Navin K. Kapur

March 06, 2024

Presentation THT 2024

Regulatory Matters Related to Monitoring Devices

Presenter: Liviu Klein

March 06, 2024

Presentation THT 2024

New Endpoints and Experimental Designs for Devices for Chronic Heart Failure (Breakthrough)

Presenter: William T. Abraham

March 06, 2024

Presentation THT 2024

Inclusion Criteria and Endpoints for Trials of Devices to Treat ADHF

Presenter: Maria Rosa Costanzo

March 06, 2024

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

Presentation THT 2024

Updates from Triluminate and TRISCEND II: Perspectives from the FDA Panel

Presenter: Susheel K. Kodali

March 04, 2024

Presentation THT 2024

FDA-Approved But Less Frequently Used Device Therapies to Treat HFrEF: Challenges and Opportunities

Presenter: Michael R. Zile

March 04, 2024

Presentation THT 2023

What Are the Pros and Cons of the Win Ratio as the Primary Endpoint for Pivotal Heart Failure Trial

Presenter: Mandeep Mehra

March 20, 2023

Presentation THT 2023

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

Presenter: William Abraham

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Changfu Wu

March 20, 2023

Presentation THT 2023

FDA Guidance on Meaningful Representation in Clinical Trials

Presenter: Bram Zuckerman

March 20, 2023

Presentation THT 2023

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

Presenter: Graham Nichol

March 20, 2023

Presentation THT 2023

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

Presenter: Navin Kapur

March 20, 2023

Presentation THT 2023

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

Presenter: Gregg Stone

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Mauro Moscucci

March 20, 2023

Presentation THT 2023

What Are Clinically Meaningful and Practical Pivotal Trial Endpoints for Effectiveness and Safety to Demonstrate an Acceptable Benefit-Risk Profile?

Presenter: Maria Rosa Costanzo

March 20, 2023

Presentation THT 2023

Invasive Investigational Device IDE Studies: For Diuretic-Resistant Patients Only?

Presenter: Ulrich Jorde

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Meir Shinnar

March 20, 2023

News Conference News THT 2022

Xenotransplant of Pig Heart ‘Just Baby Steps,’ Lead Surgeon Says

Yael L. Maxwell

February 07, 2022

Advertisement

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

Regulatory Issues Related to the Introduction of New Percutaneous Pumps

Regulatory Matters Related to Monitoring Devices

New Endpoints and Experimental Designs for Devices for Chronic Heart Failure (Breakthrough)

Inclusion Criteria and Endpoints for Trials of Devices to Treat ADHF

Debating the Role of T-TEER in the Sickest Patients

Updates from Triluminate and TRISCEND II: Perspectives from the FDA Panel

FDA-Approved But Less Frequently Used Device Therapies to Treat HFrEF: Challenges and Opportunities

What Are the Pros and Cons of the Win Ratio as the Primary Endpoint for Pivotal Heart Failure Trial

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

FDA Introduction

FDA Guidance on Meaningful Representation in Clinical Trials

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

FDA Introduction

What Are Clinically Meaningful and Practical Pivotal Trial Endpoints for Effectiveness and Safety to Demonstrate an Acceptable Benefit-Risk Profile?

Invasive Investigational Device IDE Studies: For Diuretic-Resistant Patients Only?

FDA Introduction

Xenotransplant of Pig Heart ‘Just Baby Steps,’ Lead Surgeon Says

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content